EXACT Therapeutics AS – Issuance of share options
OSLO, 31 August 2026: As part of the long-term incentive programme of EXACT Therapeutics AS (“The Company”), a total of 1,300,000 share options have been granted to the employees of the Company, of which 780,000 share options have been granted to primary insiders.
Each option, when exercised, gives the right to acquire one share in the Company. The strike price for the options is NOK 0.73 , equal to the volume-weighted average price of the Company’s share over the last 10 days of trading in the share and will vest over a period of up to three years.
The required form of notification and public disclosure by primary insiders related to the grant is attached to this announcement.
This information is subject to the disclosure requirements in Regulation EU 596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact: Per Walday, CEO EXACT Therapeutics per.walday@exact-tx.com
About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are currently traded on Euronext Growth Oslo (EXTX). An application for delisting of the shares has been approved by Oslo Stock Exchange, and last day of trading is 9 October, 2026. Further information may be found here: www.exact-tx.com